Cartesian Therapeutics (RNAC) Assets Average (2016 - 2026)
Cartesian Therapeutics (RNAC) posted quarterly Assets Average of $292.4 million for Q1 2026, down 30.72% year-over-year from $422.1 million in Q1 2025, and down 12.6% quarter-over-quarter from $334.5 million in Q4 2025.
Cartesian Therapeutics (RNAC) Assets Average (2016 - 2026) Analysis & Trends
Cartesian Therapeutics (RNAC) has reported Assets Average for 11 consecutive years, with $292.4 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Assets Average fell 30.72% year-over-year to $292.4 million; the TTM figure through Mar 2026 stood at $292.4 million (down 30.72% YoY), while the FY2025 annual figure was $365.7 million, down 1.17% from the prior year.
- Assets Average declined to $292.4 million in Q1 2026 per RNAC's latest filing, from $334.5 million in the prior quarter.
- Across five years, Assets Average topped out at $445.2 million in Q4 2024 and bottomed at $122.8 million in Q3 2023.
- Historically, Assets Average has averaged $272.9 million across 5 years, with a median of $292.4 million in 2026.
- Annual changes were most pronounced in 2023 — Assets Average tumbled 32.97% — and 2024, when it jumped 227.06%.
- Cartesian Therapeutics' Assets Average stood at $172.1 million in 2022, then increased by 19.45% to $205.5 million in 2023, then surged by 116.58% to $445.2 million in 2024, then slipped by 24.85% to $334.5 million in 2025, then fell by 12.6% to $292.4 million in 2026.
- Business Quant data shows RNAC's Assets Average at $292.4 million in Q1 2026, $334.5 million in Q4 2025, and $380.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 3.29 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 8.86 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 16.08 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.82 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 5.34 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 2.09 Bn |
| 10 | Cartesian Therapeutics | 265.54 Mn | 265.54 Mn | - | 303.51 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 303.51 Mn |
| Mar 31, 2026 | 292.40 Mn |
| Dec 31, 2025 | 334.54 Mn |
| Sep 30, 2025 | 380.78 Mn |
| Jun 30, 2025 | 399.01 Mn |
| Mar 31, 2025 | 422.08 Mn |
| Dec 31, 2024 | 445.17 Mn |
| Sep 30, 2024 | 401.53 Mn |
| Jun 30, 2024 | 336.47 Mn |
| Mar 31, 2024 | 315.13 Mn |
| Dec 31, 2023 | 205.54 Mn |
| Sep 30, 2023 | 122.77 Mn |
| Jun 30, 2023 | 147.60 Mn |
| Mar 31, 2023 | 160.79 Mn |
| Dec 31, 2022 | 172.08 Mn |
| Sep 30, 2022 | 183.17 Mn |
| Jun 30, 2022 | 166.88 Mn |
| Mar 31, 2022 | 152.79 Mn |
| Dec 31, 2021 | 163.52 Mn |
| Sep 30, 2021 | 173.84 Mn |